Abstracts tagged "Cohort Study"

Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Jing Xue¹, Hongzhi Wang², Hongbin Li³, Hui Song⁴, Yasong Li⁵, Xiaofei Shi⁶, Hongjun Zhao⁷, Feng Wei⁸, Bing Wu⁹, Hui Xiao¹⁰, Yuhua Jia⁹, Fei Xiao⁹ and Huaxiang Wu¹, ¹The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, China (People's Republic), ²The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ³The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ⁴Beijing Jishuitan Hospital, Beijing, China (People's Republic), ⁵Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of science and technology, Luoyang, China (People's Republic), ⁷Xiangya Hospital of Central South University, Changsha, China (People's Republic), ⁸Jiangmen Central Hospital Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China (People's Republic), ⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…
Abstract Number: 0178 • ACR Convergence 2020
Associations of Multimorbidity with DMARD Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness (RISE) Registry
Bryant England¹, Huifeng Yun², Lang Chen³, Kaleb Michaud¹, Ted Mikuls¹ and Jeffrey R Curtis², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Although a treat-to-target strategy is endorsed in rheumatoid arthritis (RA) treatment guidelines, its routine implementation in real-world settings, particularly in the context of multimorbidity,…
Abstract Number: 0623 • ACR Convergence 2020
Cytokine Storm: Outcomes in SARS-CoV-2 Patients Treated with Biologics in a Rheumatology Cohort
Neha Chiruvolu¹, Muntarin Karim², Patil Injean³, Sandy Lee³, Karina Torralba⁴, Christina Downey³, Mehrnaz Hojjati⁵, Loomee Doo⁵, Donna Jose⁶, Deepa Panikkath³, Micah Yu⁵, Anna Lafian⁵, Marven Cabling⁵ and Vaneet Sandhu⁷, ¹UC Riverside School of Medicine, Riverside, CA, ²Loma Linda University Health System, Loma Linda, CA, ³Loma Linda University Medical Center, Redlands, CA, ⁴Loma Linda University School of Medicine, Redlands, CA, ⁵Loma Linda University Medical Center, Loma Linda, CA, ⁶Loma Linda University Medical Center, Ontario, CA, ⁷Loma Linda University, Loma Linda, CA
Background/Purpose: Cytokine Release Syndrome (CRS) or Macrophage Activation Syndrome (MAS) is a life threating hyperinflammatory condition that can complicate rheumatic disease as well as infections…
Abstract Number: 1082 • ACR Convergence 2020
The Presence of Anti-Jo1, anti-PL7, And/or anti-MDA5 Antibodies in Idiopathic Inflammatory Myopathy Confers an Increased Risk of a Significant Restrictive Pulmonary Defect
Dmitriy Cherny¹ and Carrie Richardson¹, ¹Rush University Medical Center, Chicago, IL
Background/Purpose: A subset of patients with idiopathic inflammatory myopathy develop significant restrictive lung disease, although risk factors for this are poorly defined. Autoantibodies may be…
Abstract Number: 1492 • ACR Convergence 2020
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Report of Primary Study Outcomes
Yukiko Kimura¹, George Tomlinson², Laura Schanberg³, Mary Ellen Riordan⁴, Anne Dennos⁵, Vincent Del Gaizo⁶, Katherine Murphy⁷, Pamela F. Weiss⁸, Brian Feldman⁹ and Sarah Ringold¹⁰, ¹Hackensack Meridian School of Medicine, Hackensack, NJ, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³Duke University Medical Center, Durham, NC, ⁴Hackensack University Medical Center, Westwood, NJ, ⁵Duke University, Durham, NC, ⁶Childhood Arthritis & Rheumatology Research Alliance (CARRA), Whitehouse Station, NJ, ⁷Lousiana Department of Public Health, New Orleans, LA, ⁸Children's Hospital of Philadelphia, Philadelphia, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Seattle Children's, Seattle, WA
Background/Purpose: There is uncertainty regarding when to start biologic medications for polyarticular juvenile idiopathic arthritis (P-JIA). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed…
Abstract Number: 1902 • ACR Convergence 2020
Determinants of Physician Global Assessment and Influence of Contextual Factors in Early Axial Spondyloarthritis
Fumio Hirano¹, Robert Landewé², Floris van Gaalen³, Désirée van der Heijde⁴, Cecile Gaujoux-Viala⁵ and Sofia Ramiro⁶, ¹Leiden University Medical Center (LUMC), Leiden, Zuid-Holland, Netherlands, ²Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ³Leiden University Medical Center (LUMC), Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, CHU Nîmes, University of Montpellier-Nîmes, France, EA2415, University of Montpellier, Montpellier, France, Nîmes, France, ⁶Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: In rheumatic and musculoskeletal diseases, physician global assessment (PhGA) is a major factor of treatment decision. However, it is not well-known which disease manifestations…
Abstract Number: 0206 • ACR Convergence 2020
Fifty-Two Week Outcomes of Biologic-Naïve RA Patients Treated with Subcutaneous Abatacept in Japanese Multicenter Investigational Study (ORIGAMI Study)
Naoto Tamura¹, Eiichi Tanaka², Eisuke Inoue³, Yuri Yoshizawa⁴, Shigeru Matsumoto⁵, Hisashi Yamanaka⁶ and Masayoshi Harigai⁷, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyō, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Bristol-Myers Squibb K.K., Tokyo, Japan, ⁵Ono Pharmaceutical Co., Ltd., Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Rheumatology, Sanno Medical Center, Tokyo, Japan, ⁷Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Long-term clinical benefit and patient-reported outcomes (PRO) of subcutaneously-injected abatacept (ABA) in patients with RA in a real-world setting are of therapeutic interest. We…
Abstract Number: 0630 • ACR Convergence 2020
“No Benefit from a Strict Immobilization in Vertebral Osteomyelitis” Vertebral Immobilization and Neurological Complication in Acute Pyogenic Vertebral Osteomyelitis: SPONDIMMO, a Prospective Cohort of 250 Patients
Adrien Le Pluart¹, COIFFIER Guillaume², Christelle Darrieutort¹, CORMIER Grégoire³, GODOT Sophie⁴, Sebastien Ottaviani⁵, Gaetane Nocturne⁶, MEROT Oriane⁷, COUDERC Marion⁸, HOPPE Emmanuel⁹, MULLEMAN Denis¹⁰, Benoit Le Goff¹¹ and Geraldine Bart¹², ¹Nantes University Hospital Center, Nantes, France, ²Rennes University Hospital Center, Rennes, France, ³La Roche Sur Yon Hospital Center, La Roche Sur Yon, France, ⁴Paris Croix Saint Simon Hospital Center, Paris, France, ⁵Rheumatology Department, Bichat hospital, APHP, Paris, France, ⁶Rheumatology Department, Bicetre Hospital, APHP, France, Le Kremlin-Bicêtre, France, ⁷Saint Nazaire Hospital Center, Saint-Nazaire, Pays de la Loire, France, ⁸Clermont Ferrant University Hospital Center, Clermont Ferrand, France, ⁹Angers University Hospital Center, Angers, France, ¹⁰Tours University Hospital Center, Tours, France, ¹¹Nantes University Hospital, Nantes, Pays de la Loire, France, ¹²Rennes University Hospital Center, Rennes, Bretagne, France
Background/Purpose: Vertebral osteomyelitis (VO) can be associated with neurological complications. We showed in a previous study that they occurred in 40% of patients with VO.…
Abstract Number: 1108 • ACR Convergence 2020
Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening
Yves Henrotin¹, Anne-Christine Hick², Berenice Costes³, Alain Labasse³, Thierry Conrozier⁴, Michel Malaise⁵, Yves Maugars⁶, Franz Pelousse⁷, Jean-Marc Lemaire⁸, Cedric Tits⁹, Thibault Helleputte⁹ and Damien Loeuille¹⁰, ¹University of Liège, Liège, Belgium, ²Artialis SA, Liège, Belgium, ³Artialis SA, Liege, Belgium, ⁴5. Department of Rheumatology, Hôpital Nord Franche-Comté, Belfort, France, ⁵University of Liège, Liege, Belgium, ⁶Service de rhumatologie, Hôtel-Dieu, CHU de Nantes, Nantes, France, ⁷SODIRAY, Solution Diagnostique Radiologique, Liège, Belgium, ⁸SODIRAY, Solution Diagnostique Radiologique, Liege, Belgium, ⁹Data-Driven Precision Medicine, DNAlytics, Louvain-la-Neuve, Belgium, ¹⁰CHU NANCY Rheumatology, NANCY
Background/Purpose: To identify if biochemical markers s-Coll2-1, a peptide of type collagen and its nitrated from, s-Coll2-1NO2 are associated to knee osteoarthritis (OA), focusing on…
Abstract Number: 1498 • ACR Convergence 2020
Pregnancy Outcomes in Patients with Axial Spondyloarthritis – a First Analysis of a European Collaboration of Pregnancy Registries
Yvette Meissner¹, Nathalie Costedoat-Chalumeau², Frauke Foerger³, Doreen Goll⁴, Anna Molto⁵, Rebecca Özdemir⁶, Marianne Wallenius⁷, Anja Strangfeld⁸ and Rebecca Fischer-Betz⁹, ¹Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ²APHP, Université de Paris, Paris, France, ³University Hospital and University of Bern, Bern, Switzerland, Bern, Switzerland, ⁴Patient Research Partner, Berlin, Germany, ⁵Rheumatology Department, Cochin Hospital, Paris, Paris, France, ⁶Patient Research Partner, Duisburg, Germany, ⁷University Hospital and Norwegian University of Science and Technology, Trondheim, Norway, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹Department of Rheumatology and Hiller Research Unit Rheumatology, Heinrich Heine University, Duesseldorf, Germany, Duesseldorf, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) can affect women in their childbearing age. Data on pregnancy in axSpA patients are mainly retrospective and highly heterogeneous [1]. The…
Abstract Number: 2035 • ACR Convergence 2020
Exploring Stratification Strategies for Early Diffuse Systemic Sclerosis Clinical Trial Design
Robyn Domsic¹, Shiyao Gao², Maureen Laffoon², Steven Wisniewski³, Robert Lafyatis⁴, Virginia Steen⁵ and Thomas Medsger⁶, ¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ⁴University of Pittsburgh, Arlington, MA, ⁵Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁶University of Pittsburgh School of Medicine, Verona, PA
Background/Purpose: Clinical trials in early diffuse systemic sclerosis (SSc) using the modified Rodnan skin score (mRSS) as the primary outcome have been largely negative. This…
Abstract Number: 0225 • ACR Convergence 2020
Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study
Hawazin Alhazzani¹, Reem Tashkandi¹, Lamia Alzamel¹, Haya Almalag¹, Shiekha Alaujan¹, Abdurhman Alarfaj¹, Hussain Alarfaj¹ and Mohammed Omair¹, ¹King Saud University, Riyadh, Saudi Arabia
Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…
Abstract Number: 0637 • ACR Convergence 2020
Clinical and Treatment Features of Rheumatoid Arthritis in HIV-Infected Individuals Followed Longitudinally over Time
Benjamin Naovarat¹, Francis Williams¹ and John Reveille², ¹The University of Texas McGovern Medical School, Houston, TX, ²Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: With the successful treatment of HIV-1 infection with combination anti-retroviral treatment, immune-mediated diseases that were rarely encountered in HIV positive individuals in the pre-treatment…
Abstract Number: 1109 • ACR Convergence 2020
Pain in Women with Knee and/or Hip Osteoarthritis Is Related to Systemic Inflammation and to Adipose Tissue Dysfunction and Distribution: A Cross-sectional Metabolic Biomarkers Cohort Study
Jeremie Sellam¹, Anne-Christine Rat², Soraya Fellahi³, Jean-Philippe Bastard⁴, Willy NGUEYON SIME⁵, Hang Korng EA⁶, Pascal Richette⁷, Jacqueline Capeau⁸, Francis Guillemin⁹ and Francis Berenbaum¹, ¹AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ²Universite de Caen Normandie and Université de Lorraine, EA 4360, Caen, France, ³AP-HP INSERM, Paris, France, ⁴INSERM AP-HP UPEC, Paris, France, ⁵Universite de Lorraine, INSERM, CIC, Nancy, France, ⁶Universite de Paris, AP-HP, INSERM, paris, France, ⁷Department of Rheumatology, Lariboisière Hospital, Paris, France, ⁸INSERM Sorbonne Universite, Paris, France, ⁹Universite de Lorraine CIC INSERM, Nancy, France
Background/Purpose: Beyond the link between metabolic diseases and osteoarthritis (OA) risk, some studies have suggested an association between metabolic syndrome or visceral obesity and OA-related…
Abstract Number: 1567 • ACR Convergence 2020
Association of Blood Count Biomarkers and Clinical Features with Immune Related Adverse Events (irAEs) in Patients with Cancer Treated with Checkpoint Inhibitors (CPI)
Despina Michailidou¹, Ali R Khaki², Guangyu Wang³, Leonidas Diamantopoulos² and Petros Grivas², ¹Division of Rheumatology, University of Washington, Seattle, Washington, Seattle, WA, ²Division of Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, Seattle, WA, ³Department of Biostatistics, University of Washington, Seattle, Washington, Seattle, WA
Background/Purpose: Patients with cancer treated with CPI can develop irAEs. Since immune changes may impact blood counts and ratios, we hypothesized that those would be…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].